Lv1
10 积分 2022-10-13 加入
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
28天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
28天前
已完结
皖公网安备34019202002308
